Q-omics provides the consensus-scored SCAF4 profile across patient tissues and cancer cell-line models. SCAF4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SCAF4 is differentially expressed in 14, with the highest sampling consensus in LIHC. Additionally, SCAF4 protein abundance shows 24,137 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, LIHC, and GBM as cancer lineages where SCAF4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCAF4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCAF4 survival associations across molecular data types. SCAF4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCAF4 RNA expression–survival associations across cancer types. High SCAF4 expression shows unfavorable associations in KIRP, UVM, HNSC, MESO and LGG, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for SCAF4 RNA expression.
This table summarizes SCAF4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SCAF4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCAF4 shows lower tumor expression in THCA and higher tumor expression in LIHC, STAD, BLCA, KIRC and BRCA. The LIHC box plot shows higher SCAF4 RNA expression in tumor versus normal tissue (log2 FC = +0.351, t-test p < 0.001).
This table shows molecular features associated with SCAF4 in patient tissues and cancer cell lines. In patient samples, SCAF4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SCAF4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
